β-Blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 4, 1999, Pages 534-539

  Fogari, R ^a,b   Zoppi, A ^a   Corradi, L ^a   Preti, P ^a   Mugellini, A ^a   Lusardi, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Electrophisiology and Cardiac Pacing Unit Istituto di Cura Città di Pavia   (Italy)

Author keywords

Blockers; Hypercholesterolemia; Hypertension; Plasma lipids

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CELIPROLOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPRANOLOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANALYSIS OF VARIANCE; ATENOLOL; BISOPROLOL; CELIPROLOL; DOUBLE-BLIND METHOD; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PROPRANOLOL;

EID: 0032965116     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199904000-00004     Document Type: Article

References (38)

1. Kannel WB. Influence of multiple risk factors on the hazard of hypertension. J Cardiovasc Pharmacol 1990;16(suppl 5):S53-7.
2. Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National Education Program Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 1991;114:224-37.
3. Van Brummelen P. Lipid changes induced by Beta-blockers. Curr Opin Cardiol 1988;3(suppl 2):S13-7.
4. Ames RP. Antihypertensive drugs and lipid profiles. Am J Hypertens 1988;1:421-7.
5. Chait A. Effects of antihypertensive agents on serum lipids and lipoproteins. Am. J Med 1989;86(suppl 1B):5-7.
6. Lardinois CK, Johns JP. Cardiac drug effects on lipids. Curr Opin Lipidol 1992;3:274-8.
7. Kasiske BL, Ma JZ, Kalil RS, Lonis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-41.
8. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of hypertension detection and follow-up program: I-reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71.
9. National Heart Foundation of Australia Management Committee. The Australian Therapeutic Trial in mild Hypertension. Lancet 1980;1:1261-7.
10. Medical Research Council Working Party. MRC trial of mild hypertension; principal results. Br Med J 1985;291:97-104.
11. IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:279-92.
12. Weinberger MH. Antihypertensive therapy and lipids: paradoxical influences on cardiovascular disease risk. Am J Med 1986;SO(suppl 2A):64-70.
13. Day JL, Simpson N, Metcalfe J, Page RL. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1979;1:77-80.
14. Leren P, Helgeland A, Holme I, Foss PO, Hjermann I, Lund-Larsen PG. Effect of propranolol and prazosin on blood lipids: the Oslo Study. Lancet 1980;2:4-6.
15. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanism in control of plasma lipids concentrations. Br Med J 1992;284:1145-8.
16. Fager G, Berglund G, Bondjers G, et al. Effects of antihypertensive therapy on serum lipoproteins: treatment with metoprolol, propranolol and hydrochlorothiazide. Artery 1983;11:283-6.
17. Durrington PN, Brownlee WC, Large DM. Short-term effects of beta-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hypertriglyceridemic patients and in normal men. Clin Sci 1985;69:713-9.
18. Pasotti C, Zoppi A, Capra A, Rebagliati M, Fogari R. Effect of beta-blockers on plasma lipids. Int J Clin Pharmacol Ther Toxicol 1986;24:448-52.
19. Fogari R, Zoppi A, Pasotti C, et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989;14(suppl 7):S28-32.
20. Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990;16(suppl 5):S76-80.
21. Pasotti C, Capra A, Fiorella G, Viberti C, Chierichetti SM. Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Br J Clin Pharmacol 1982;13(suppl 2):435S-9S.
22. Van Brummelen P. The relevance of intrinsic sympathomimetic activity for beta-blocker induced changes in plasma lipids. J Cardiovasc Pharmacol 1983;5(suppl 1):S51-5.
23. Van Brummelen P, Bolli P, Koolen MI, Staehelin HB, Buhler FR. Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients. Br J Clin Pharmacol 1984;17:86-8.
24. Hitzenberger C. The effects of the beta-adrenoceptor blocking agent celiprolol on blood lipids. Br J Clin Prac 1985;36(suppl 40):85-7.
25. Herrmann JM, Mayer EO. A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. Am Heart J 1988;116:1416-21.
26. Fogari R, Zoppi A, Tettamanti F, Malamani G, Pasotti C. The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels. Cardiovasc Drugs Ther 1990;4:1287-90.
27. Hunninghake DB. Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins. Am Heart J 1991;121:696-701.
28. Vyssoulis GP, Karpanou EA, Pitsavos CE, Skoumas JN, Paleologos AA, Toutouzas PK. Differentiation of beta-blocker effects on serum lipids and apoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles. Eur Heart J 1992;13:1506-13.
29. Dujovne CA, Eff J, Ferraro L, et al. Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects. Am J Cardiol 1993;72:1131-6.
30. Lijnen P, Van Hoof R, Amery A. Effects of celiprolol vs nifedipine on serum lipoproteins in patients with mild to moderate hypertension. Cardiovasc Drugs Ther 1994;8:509-13.
31. Johnston GD, Vyssoulis G, Feely J, Holden RD, Radley DR. Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised, double-blind long-term parallel group trial. J Hum Hypertens 1995;9:123-9.
32. Roschlau P. Enzymatische Bestimmung des Gesamtcholesterin in serum. Z Klin Chem Klin Biochem 1974;12:403.
33. Viikari J. Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation. Scand J Clin Lab Invest 1976;36:265-71.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
35. 3H(+)carazolol binding to beta-adrenergic receptors: application to study beta-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circ Res 1981;49:326-36.
36. Frithz G, Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(suppl 11):S134-8.
37. Lohmann FW, Loesment WA, Kaehler H. Beta-receptor blockade, physical activity and metabolism. J Cardiovasc Pharmacol 1990;16(suppl 5):S45-52.
38. Lijnen P. Biochemical mechanisms involved in the beta-blocker induced changes in serum lipoproteins. Am Heart J 1992;124: 549-56.